seattle genetics inc (SGEN) Key Developments
Seattle Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
Apr 30 15
Seattle Genetics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues were $82.2 million, compared to $68.3 million in the first quarter of 2014. Net loss was $21.7 million, or $0.17 per share, compared to a net loss of $16.3 million, or $0.13 per share, for the first quarter of 2014. Loss from operations was $21.743 million against $16.371 million a year ago.
Seattle Genetics, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 02:25 PM
Apr 29 15
Seattle Genetics, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 02:25 PM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Jonathan Drachman, Chief Medical Officer and Executive Vice President of Research & Development.
Seattle Genetics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM
Apr 28 15
Seattle Genetics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Clay B. Siegall, Co-Founder, Chairman, Chief Executive Officer and President.
Seattle Genetics, Inc. Presents at UBS Global Healthcare Conference, May-19-2015 02:00 PM
Apr 21 15
Seattle Genetics, Inc. Presents at UBS Global Healthcare Conference, May-19-2015 02:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Eric L. Dobmeier, Chief Operating Officer.
FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse
Apr 20 15
Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in the AETHERA setting for the post-transplant consolidation treatment of Hodgkin lymphoma (HL) patients at high risk of relapse or progression. The FDA granted Priority Review for the application and the Prescription Drug User Fee Act (PDUFA) target action date is August 18, 2015. The submission of the supplemental BLA is based on positive results from a phase 3 clinical trial called AETHERA that was designed to determine if 16 cycles of ADCETRIS as consolidation therapy immediately following an autologous stem cell transplant (ASCT) could extend progression-free survival (PFS) in HL patients at high risk of relapse or progression. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL), as well as other lymphoma subtypes. ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT.